Physician profile
Poorvi King
NPI 1972999126
$1,434.34
in general payments reported to CMS, 2019-2025
15 companies · $247 in 2025
The $247 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2021: $65.81 · 2022: $381 · 2023: $350 · 2024: $22.18 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $602 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.65 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $239.92 | 2019 | |
| Genzyme Corporation | $210.95 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $166.89 | 2022-2023 | Dupixent |
| Glaxosmithkline, LLC. | $165.50 | 2022-2025 | Nucala, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.91 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $152.82 | 2022-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $97.00 | 2019-2023 | Zerbaxa, Recarbrio |
| Baxter Healthcare | $67.28 | 2022-2024 | Starling System, Hillrom - Vest System Model 105 Home Care |
| Mylan Specialty L.P. | $39.83 | 2023 | Yupelri |
| Insmed, INC. | $32.94 | 2025 | Brinsupri, Arikayce |
| Melinta Therapeutics, LLC | $29.54 | 2022-2023 | Vabomere, Orbactiv, Kimyrsa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.37 | 2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $21.07 | 2023 | Opsumit, Uptravi |
| Phadia US INC. | $18.42 | 2023 | Immunocap |
| Amgen INC. | $15.90 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Poorvi King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.